News and Announcements
Pooled Mortgage Trust delivers 11.22% return
- Published April 25, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Private Mortgages Australia, a boutique Mortgage Manager specialising in sourcing and managing short-term commercial loans secured by Australian real estate mortgages, has announced a quarterly result of 11.22% p.a. (2.74% this quarter) for the PMAC Trust. The PMAC Trust is a pooled mortgage fund that offers individual investors the benefit of diversification of mortgage transactions.
The Trust has delivered the following return to investors in the past three years:
- FY 2016: 12.50% Annualised Return
- FY 2017: 14.57% Annualised Return
- FY 2018: 12.21% Annualised Return
Investing in the Trust has traditionally only been available to Wholesale or Sophisticated Investors, however, a Retail Feeder Fund has recently been made available for Retail Investors. Private Mortgages Australia are currently assessing a large number of new loan opportunities and therefore accepting additional investments. They have decided to offer an allocation of 1M Units with no Application Fee so there has never been a better time to invest in the PMAC Trust.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
